Tg Therapeutics, Inc. · NASDAQ:TGTX
Tg Therapeutics — Investor Day (June 2018)
8 slides from Tg Therapeutics's investor day presentation, Jun 4, 2018
Slide 1: TG Therapeutics Investor & Analyst Event June 2018
Si £ TG Therapeutics Investor & Analyst Event June 2018 Michael S. Weiss Executive Chairman & CEO QUNITY® QUNITY® TG THERAPEUTICS TG THERAPEUTICS MMR
Slide 2: Forward Looking Safe Harbor Statement
Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as “anticipates”, “expects”, “plans”, “bel
Slide 3: Topic / Presenter
Topic Presenter Welcome / Introductions HUSRERIS. WEES, CEO TG Therapeutics KI Intolerant Review Anthony Mato, MD Emerging Challenges in CLL: Drug Drug Interactions Alexey Danilov, MD, PhD Questions & Answer Session Closing Remarks Michael S. Weiss TG Therapeutics 3 P Teter
Slide 4: PI3K(delta)
CK: PI3K(delta Pee sc
Slide 5: Biopharmaceutical company focused on B-cell cancers (CLL and NHL)
= Biopharmaceutical company focused on B-cell cancers (CLL and NHL) & autoimmune-related diseases (MS, RA, Lupus) » Headquarters: New York, NY » NASDAQ: TGTX = Developing portfolio of B-cell targeted agents » Ublituximab (TG-1101) — Novel Glycoengineered, Anti-CD20 monoclonal antibody » Enhanced ADC
Slide 6: Clinical program updates and upcoming milestones
‘Te Therapeutes Opa » UNITY-CLL » On target for ORR data this summer = GENUINE » Filing decision pending outcome of UNITY-CLL and KOL outreach » Our goal is to put our best filing package in first (if possible) » Including, filing accelerated approval based on the UNITY-CLL ORR data and/or GENUINE O
Slide 7: MS Program and Pipeline Update
er = MS Program » Phase 2 final data expected before YE » ULTIMATE | & Il Phase 3 Program Update! » Complete enrollment now targeted by YE 2018 (prior guidance by end of 1Q19) = Pipeline Update » Anti PD-L1 monoclonal antibody: » Phase 1 dose escalation complete = Commencement of heme focused cohort
Slide 8: ASCO and EHA presentations
ASCO: Poster: A Phase 2 Study to assess the safety and efficacy of umbralisib (TGR-1202) in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy (Abstract #: S808) » Date & Time: Monday June 4, 2018; 8:00 — 11:30 CT EHA: Oral: A Phase 2 Stu